Evidence map›Paper›PMID 41803958›Full record

ArticleJournal of biological engineering2026

A novel device for in-situ on-demand hydrogen sulfide generation and delivery to increase tissue perfusion to chronic wounds.

Matthew Justus, Debra Friedrichsen, Bill Brooks, Grayson Silaski, Robert Beckius, Pierce Massie, Carolyn Pace, Deepali Kulkarni, Trevor Self, Mildred Mattox and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of biological engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Matthew JustusDepartment of Surgery, University of New Mexico, Albuquerque, NM, 87131, USA.
Debra FriedrichsenExhalix LLC, Corvallis, OR, 97330, USA.
Bill BrooksExhalix LLC, Corvallis, OR, 97330, USA.
Grayson SilaskiExhalix LLC, Corvallis, OR, 97330, USA.
Robert BeckiusExhalix LLC, Corvallis, OR, 97330, USA.
Pierce MassieDepartment of Surgery, University of New Mexico, Albuquerque, NM, 87131, USA.
Carolyn PaceDepartment of Surgery, University of New Mexico, Albuquerque, NM, 87131, USA.
Deepali KulkarniDepartment of Surgery, University of New Mexico, Albuquerque, NM, 87131, USA.
Trevor SelfDepartment of Physiology and Pharmacology, Texas A&M University, College Station, TX, 77843-4466, USA.
Mildred MattoxDepartment of Physiology and Pharmacology, Texas A&M University, College Station, TX, 77843-4466, USA.
Jeffrey BrayDepartment of Physiology and Pharmacology, Texas A&M University, College Station, TX, 77843-4466, USA.
Erin Risotto-UrbanowiczDepartment of Surgery, University of New Mexico, Albuquerque, NM, 87131, USA.
Andrea Iturralde-CarilloDepartment of Surgery, University of New Mexico, Albuquerque, NM, 87131, USA.
Jenna MarekDepartment of Surgery, University of New Mexico, Albuquerque, NM, 87131, USA.
Brittany CoffmanDepartment of Pathology, Veterans Affairs Hospital, Albuquerque, NM, 87131, USA.
Cristine HeapsDepartment of Physiology and Pharmacology, Texas A&M University, College Station, TX, 77843-4466, USA.
Heather FergusonQRT Consulting Group LLC, Marengo, USA.
Reza ShekarrizExhalix LLC, Corvallis, OR, 97330, USA.
Nancy KanagyDepartment of Cell Biology and Physiology, University of New Mexico, Albuquerque, NM, 87131, USA.
Ross ClarkDepartment of Surgery, University of New Mexico, Albuquerque, NM, 87131, USA. rmclark@salud.unm.edu.

Funding

HEALS™: An Active Hydrogen Sulfide Delivery Technique for Accelerated, Effective Wound HealingR44GM144027 · NIGMS · EXHALIX, LLC · PI SHEKARRIZ, REZA · 2023 to 2024
$2.0M
Repair by Local Infusion of Sulfides (ReLIS™) for Treatment of Disadvantaged Surgical IncisionsR43AG076027 · NIA · EXHALIX, LLC · PI SHEKARRIZ, REZA · 2022 to 2022
$300k
HEALS™: An Active Hydrogen Sulfide Delivery Technique for Accelerated, Effective Wound HealingR43GM144027 · NIGMS · EXHALIX, LLC · PI SHEKARRIZ, REZA · 2021 to 2021
$300k
NIA NIH HHS R43 AG076027NIGMS NIH HHS R43 GM144027NIGMS NIH HHS R44 GM144027NIH HHS GM144027, AG076027NIH HHS GM144027, AG076027, K12TR005467
6 · The paper itself

Abstract

backgroundThere is significant evidence linking deficiency in endogenous hydrogen sulfide (H2S) to delayed healing of wounds. Systemic administration of H2S donors has been shown to markedly improve the healing rate of ischemic open wounds. This paper describes a novel H2S therapy approach, namely H2EALS™, as an exogenous supplement to accelerate healing. H2EALS™ employs a controllable process for in-situ conversion of a metal sulfide coating to H2S gas for safe and effective H2S treatment.

methodsThe core technology topically releases a targeted quantity of H2S molecules within the dressing for absorption into the open wound using control and delivery protocol specified by the end-user. Benchtop studies have evaluated precision in the rate and amount of H2S released and the degree of control, all required for safe treatment. In preclinical studies using rodent and swine models, the potential widespread dispersion of the H2S delivered was evaluated with an H2S sensing approach, while the physiological dose-response in terms of absorption and perfusion within the wound and periwound regions were examined using both H2S measurement and Laser Speckle Contrast Imaging (LSCI).

resultsBenchtop studies on H2EALS™ demonstrate clinically relevant performance durability and control over H2S dose administered. With low power requirement, high dosage control, and relatively low dose-to-dose variability, electroactive H2S sources with capacity of > 2 µmol/application were fabricated to last beyond a typical 14-day wound treatment period. In-vivo studies on open wounds in Sprague-Dawley rats treated at 25 to 100 nmol/dose indicated rapid tissue absorption of H2S gas. Real-time breath- and skin-emitted H2S measured on swine revealed no evidence of widespread dispersion when up to 500 nmol/dose was delivered directly to an 8-mm open wound.

conclusionOur results emphasize the need for informed delivery and absorption of H2S to the target tissue and we demonstrate the potential of the H2EALS™ technology of safe and effective H2S treatment of open wounds and in acceleration of wound healing. The results are a partial contribution to evaluating the impact of H2EALS™ on wound healing acceleration and tissue repair.

Indexed as

Blood perfusionChronic woundsElectrocatalysisHydrogen sulfide deliveryMicrovascular flowNon-invasiveRodentSwineWound treatment

Identifiers

PMID41803958
PMCPMC13085374

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.